MONTVALE, N.J., Jan. 15, 2009 (GLOBE NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electrotherapy systems, today announced that previously announced results from a double-blind, randomized, placebo-controlled and prospective clinical trial on “no-option” cardiac patients utilizing the Company’s proprietary targeted pulsed electromagnetic field (tPEMF(tm)) technology have been peer reviewed and accepted for presentation at the American College of Cardiology (ACC) 58th Annual Scientific Meeting, March 29-31, 2009 in Orlando, Florida.
